Completed PHASE1 INTERVENTIONAL 4-arm NCT05995444

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

A Phase 1, Single-Dose, Randomized, Placebo- and Positive-Control, Four-Way, Crossover Study for the Evaluation of the Effect of Epetraborole on QT Intervals in Healthy Adult Subjects

Sponsor: AN2 Therapeutics, Inc

Conditions Healthy Volunteers

Interventions Epetraborole Epetraborole and matching placebo Moxifloxacin Placebo

Updated 4 times since 2023 Last updated: Dec 20, 2023 Started: Jun 5, 2023 Primary completion: Jul 26, 2023 Completion: Aug 3, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by AN2 Therapeutics, Inc and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1
Sep 2023 — Jan 2024 [monthly]

Completed PHASE1

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AN2 Therapeutics, Inc

Data source: AN2 Therapeutics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States